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ABSTRACT 44 
Objective: To compare the effects on walking of Functional Electrical Stimulation (FES) 45 
and Ankle Foot Orthoses (AFO) for foot-drop of central neurological origin, assessed in 46 
terms of unassisted walking behaviours compared with assisted walking following a 47 
period of use (combined-orthotic effects). 48 
Data Sources: MEDLINE, AMED, CINAHL, Cochrane Central Register of Controlled 49 
Trials, Scopus, REHABDATA, PEDro, NIHR Centre for Reviews and Dissemination 50 
and clinicaltrials.gov. plus reference list, journal, author and citation searches. 51 
Study Selection: English language comparative Randomised Controlled Trials (RCTs). 52 
Data Synthesis: Seven RCTs were eligible for inclusion. Two of these reported different 53 
results from the same trial and another two reported results from different follow up 54 
periods so were combined; resulting in five synthesised trials with 815 stroke 55 
participants. Meta-analyses of data from the final assessment in each study and three 56 
overlapping time-points showed comparable improvements in walking speed over ten 57 
metres (p=0.04-0.95), functional exercise capacity (p=0.10-0.31), timed up-and-go 58 
(p=0.812 and p=0.539) and perceived mobility (p=0.80) for both interventions.  59 
Conclusion: Data suggest that, in contrast to assumptions that predict FES superiority, 60 
AFOs have equally positive combined-orthotic effects as FES on key walking measures 61 
for foot-drop caused by stroke. However, further long-term, high-quality RCTs are 62 
required. These should focus on measuring the mechanisms-of-action; whether there is 63 
translation of improvements in impairment to function, plus detailed reporting of the 64 
devices used across diagnoses. Only then can robust clinical recommendations be made.  65 
Key words: electrical stimulation therapy, nervous system diseases, stroke, walking, foot 66 
drop, systematic review, meta-analysis. 67 
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MAIN TEXT 68 
 69 
 70 
INTRODUCTION 71 
 72 
Conditions such as stroke, brain injury (BI), multiple sclerosis (MS), spinal cord injury (SCI) 73 
and cerebral palsy (CP) affect upper motor neuronal pathways (1) and are collectively 74 
referred to as pathologies of central neurological origin (CNO) (2). In the United Kingdom 75 
(UK) there are approximately 1.2 million people living with stroke (3), 100,000 MS and 76 
40,000 SCI (4), there are 160,000 BI admissions per year (5), and 1 in 400 people have CP 77 
(6). Foot-drop is a common impairment seen across these conditions (7) and although 78 
prevalence data in some of the CNO conditions is very limited, a commonly cited figure 79 
suggests that it is seen in 20-30% of people with stroke (7, 8) 80 
Foot-drop is categorized as an inability to dorsiflex the foot, with or without excessive 81 
inversion and is most commonly caused by weakness in the dorsiflexor (and evertor) and/or 82 
overactivity in the plantarflexor (and invertor) muscle groups. Foot-drop results in walking 83 
being slower, less efficient and potentially unsafe (7); as foot clearance during swing and 84 
initial foot contact at the start of the stance phase are compromised. These factors have been 85 
associated with an increased risk of falls (7), reduced quality of life (7, 9) and increased 86 
levels of mortality (10). 87 
Current practice in the treatment of foot-drop normally involves a form of ankle foot orthosis 88 
(AFO)(11). Functional electrical stimulation (FES) is also used but less frequently (9).  89 
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AFOs stabilise the foot and ankle and lift the toes when stepping (12). Meta-analyses have 90 
shown them to have positive effects on some aspects of walking (12, 13) but these analyses 91 
are primarily based on non-randomised control trial (RCT) evidence. AFOs have been 92 
criticised for detrimental effects on the adaptability of walking, propulsion, aesthetics and 93 
comfort (14-16) which can impact compliance and satisfaction.  94 
Foot-drop FES uses electrical pulse trains to stimulate the common peroneal nerve over key 95 
phases of  the gait cycle to correct the foot-drop impairment (17). This phasic stimulation can 96 
be delivered via surface or implanted electrodes. Foot-drop FES has been shown to have 97 
positive effects on walking speed (18, 19) but meta-analyses have also, in part, been based on 98 
non-RCT evidence. For surface systems, limitations have been cited in relation to issues with 99 
effort of setup, skin irritation and pain (20), which again affects compliance and satisfaction. 100 
Implanted systems address some of these limitations but are more costly (21). 101 
Despite their limitations both are endorsed in the management of foot-drop with clinical 102 
guidelines existing for AFO as a result of stroke (22, 23) MS (24), CP (25) and BI (26) and 103 
FES guidelines promoting use across all CNO diagnoses (2). However, these guidelines have 104 
had to rely on some non-RCT sources of evidence and as intervention specific guidelines, 105 
comparing to no treatment or physiotherapy, do not consider evidence from direct 106 
comparisons between these interventions. As a result current guidelines do not provide 107 
clinicians with a clear patient pathway. Recently a number of RCTs providing direct 108 
comparisons have been published. Furthermore, these studies have advanced our 109 
understanding of the effects these interventions may produce:   110 
a) Immediate-orthotic effects where same-day comparisons are made between AFO/FES 111 
unassisted and assisted walking behaviours  (16, 27).  112 
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b) Therapeutic effects (19, 28) where unassisted walking behaviours are compared with 113 
unassisted walking on a day some period later (16, 27).   114 
c) Training effects (16) where assisted walking behaviours are compared with assisted 115 
walking on a day some period later. 116 
d) Combined-orthotic effects (15) where unassisted walking behaviours on one day are 117 
compared with assisted walking on a day some period later (16, 27).  118 
 119 
The suggested mechanism-of-action for AFO is that the device remedies the loss of 120 
dorsiflexion/eversion by holding the foot in a neutral position but this can result in negative 121 
effects on neuromuscular control and muscle biomechanics with long-term use (29-31). 122 
Therefore, it has been assumed that they only provide immediate-orthotic effects (a) (12), a 123 
notion supported by the only known long-term AFO specific RCT in the field (32).  124 
In contrast, there are many reports of long-term neuromuscular control improvements with 125 
FES (19, 33) which are attributed to changes in neural plasticity, muscular strength and 126 
cardiovascular efficiency (31, 34, 35). The mechanism for these improvements has been 127 
hypothesised as being due to the coinciding of antidromic electrical stimulation-generated 128 
action potentials with volitional activity leading to strengthening of modifiable Hebb-129 
synapses at a segmental level (34, 36, 37).  130 
Given these proposed mechanisms-of-action it could be assumed that FES will provide a 131 
distinct advantage over AFO with long-term use. 132 
Two recent reviews (9, 38) have explored the long-term effects evidence for AFOs versus 133 
FES in stroke survivors; both concluding that there was a preference for FES but insufficient 134 
evidence to recommend one over the other. However, the first was not systematic (39) and 135 
included non-RCT studies (9) and the other did not meta-analyse; possibly due to the breadth 136 
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of question posed (38). This review (38) reported that FES was superior at conserving energy 137 
but included a paper where FES was combined with botulinum toxin (40) and another that 138 
compared FES to therapy as opposed to AFO (41).  139 
In order to provide improved clinical guidelines which will help clinicians determine which 140 
of these interventions to prescribe and what the directly comparable effects are over a period 141 
of use gold standard meta-analysis of RCT level evidence is required (42). Given that both 142 
interventions are most commonly prescribed as long-term orthotics (9, 30) and the 143 
assumption that studying long-term use will highlight any differences in walking behaviours 144 
resulting from the different mechanisms-of-action we sought to perform a systematic 145 
examination of the evidence base to address the question: 146 
Are the combined-orthotic effects on walking for foot-drop of CNO greater for FES than 147 
AFO? 148 
 149 
 150 
METHODS 151 
 152 
This review was designed according to the Preferred Reporting Items for Systematic Reviews 153 
and Meta-analyses (PRISMA) statement (43). The full review protocol can be found at: 154 
http://www.crd.york.ac.uk/PROSPERO/register_new_review.asp?RecordID=9892&UserID=155 
6114 156 
Nine electronic databases were searched. These were MEDLINE (Ovid), AMED (Ovid), 157 
CINAHL (EBSCO), Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, 158 
REHABDATA, PEDro, NIHR Centre for Reviews and Dissemination and clinicaltrials.gov. 159 
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A search strategy including controlled vocabularies related to “electric stimulation”, 160 
“walking” and “nervous system diseases” and terms such as “foot drop” and “electric* 161 
stimulat*” were used with no date limits (full search strategy available on request from the 162 
corresponding author). Reference list, citation, key author and journal searches were also 163 
completed and all searches were limited to the English language.  164 
Once duplicates were removed one reviewer (SP) screened titles and abstracts categorising 165 
each as ‘possibly’ or ‘clearly not’ relevant against the inclusion criteria (Table I). Full length 166 
articles were retrieved for ‘possibly relevant’ studies and two unmasked reviewers (SP and 167 
KH) independently assessed their eligibility (Table I) classing them as ‘relevant’, ‘definitely 168 
irrelevant’ or ‘unsure’. Different outcome measurements from the same trial reported in 169 
separate publications were treated as a single publication; as were separate publications that 170 
reported different data collection time-points within the same trial. Any disagreements or 171 
‘unsure’ publications were discussed (between SP and KH). A third reviewer was available to 172 
resolve any disagreements (LK). 173 
 174 
Table I. Inclusion Criteria. 175 
 176 
SP extracted data using a predesigned proforma; trial details extracted related to the 177 
characteristics of the included studies, participant and intervention details. Missing data 178 
and/or aspects that required clarification were requested from trial authors (14, 16, 44, 45), by 179 
SP (Appendix I). KH reviewed the extracted data for accuracy.  180 
 As an RCT-based review, and to avoid the limitations of scaled quality assessment tools (42, 181 
46), the Cochrane risk of bias assessment tool (42) was used independently by two reviewers 182 
(SP and KH) with a third reviewer (LK) available if necessary. To ensure impartiality, risk of 183 
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bias was based on published work only. Performance bias was not considered as the 184 
interventions precluded blinding of participants and measures were primarily objective (46).  185 
Outcomes across the World Health Organisation’s (WHO) International Classification of 186 
Functioning, Disability and Health (ICF) (47) were extracted. This helped to identify if there 187 
was any comparative evidence to support the assumed mechanisms-of-action and whether 188 
they translated into function. Therefore, all measurements were categorised as either being 189 
within the body functions and structures (BFS), activity or participation domain (47) by SP, 190 
using supporting literature (47-50).  All post-intervention data collection point assisted-191 
walking means and standard deviations (SD) were extracted with final-assessment data 192 
pooled for data analysis. Given the hypothesised mechanisms-of-action suggesting that FES 193 
would have greater benefits than AFO with longer-term use; broadly overlapping time-point 194 
data was also grouped for meta-analysis where possible. Standard errors were converted to 195 
SDs (14, 42, 51) and functional exercise capacity (an activity domain measurement (52)) was 196 
considered as metres walked so was converted as necessary (15).  197 
Meta-analyses were performed using RevMan 5.3® software. Where the same measurement 198 
was used across more than two trials, outcomes were combined using mean difference (MD) 199 
with 95% confidence intervals (CIs). Where an outcome was measured using different 200 
approaches, such as functional exercise capacity (distance walked in metres measured over 201 
two, three or six minutes), standardised mean difference (SMD) with 95% CIs was used. For 202 
crossover trials only pre-crossover data was extracted (15). Where there was more than one 203 
arm looking at the same intervention the similarity at baseline to the other intervention and 204 
size were used to decide which to use and the data from the most comparable group extracted 205 
(15).  206 
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Heterogeneity was examined using visual inspection of forest plot, chi² test and I² statistic. If 207 
the chi² test showed heterogeneity which the I² statistic identified as being moderate to low, 208 
(<50% (42)) a fixed-effects model was used. A random-effects model was used for 209 
heterogeneity of >50%. 210 
 211 
 212 
RESULTS 213 
 214 
1836 citations were found of which seven were eligible for inclusion. Two of these reported 215 
outcomes from the same participants (44, 53) so were grouped, and subsequently referred to 216 
by the first publication date (44). One trial published results up to six months (14) and had 217 
another publication reporting results at 12 months (51); so were also grouped. For meta-218 
analysis the relevant publication was used with the source identified by the date of the 219 
publication on the corresponding forest plot. Thus a total of five RCTs, published between 220 
2007 and 2015 with 815 participants, were available for meta-analysis (Fig. 1).  221 
 222 
Fig. 1. Flowchart of trial selection. 223 
 224 
Table II. Characteristics of included trials, participant and intervention details. 225 
 226 
 227 
Characteristics of included trials 228 
 229 
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One trial used a multiple-site crossover design (15) with two AFO arms. Data from arm 2 230 
(AFO-FES) was used as it was larger and similar to the FES group at baseline. The remaining 231 
four trials used two arm parallel RCT design, two single-site (44, 45) and two multiple-site 232 
(14, 16) (Table II). 233 
 234 
Participant details 235 
 236 
All the participants were over the age of 18 years and had suffered a stroke. Average time 237 
since diagnosis ranged from 51.7 days (45) up to 6.9 years (14, 51). Of those trials that 238 
reported hemiplegic side (16, 44, 45) there was a relatively even distribution (116:47.9% 239 
right, 126: 52.1% left). Two of the trials recruited current AFO users (16, 44) whereas the 240 
remaining four introduced the interventions to both groups for the first time (Table II).  241 
 242 
Intervention details 243 
 244 
Three of the trials (14-16, 51) reported providing “customized” AFOs prescribed by an 245 
orthotist; plus a physiotherapist for Kluding et al (16). One used off-the-shelf AFOs (45) 246 
which is appropriate practice with their, sub-acute, population (54) and one used a 247 
combination (44). No trial reported any further details of the AFOs or how prescription 248 
decisions were made; none were hinged. All-but-one study used surface FES systems (44), 249 
one trial highlighted that “clinicians” setup FES for measurement (45) but no trial reported 250 
details of setup parameters such as electrode placement, ramping, amplitude or frequency. 251 
The setting where interventions were used varied with participants from three of the studies 252 
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using the devices within their own environment (14, 15, 44, 51). One trial used them in both 253 
the participants own environment and under supervision (16) and one used them only under 254 
supervision (45). All-day-use was encouraged in all-but-one of the trials (45), some with a 255 
gradual introduction, although whether this was adhered to was not reported. Three trials 256 
provided concurrent therapy for both groups (16, 44, 45) (Table II). 257 
 258 
Methodological Quality 259 
 260 
Table III. Risk of Bias 261 
 262 
Table III summarises the quality assessment, Kluding et al (16) alone had no identified areas 263 
of high risk of bias. 264 
 265 
Table IV. Outcome measurements and intervention effects 266 
 267 
 268 
Outcome Measurements 269 
All trials utilised ICF activity domain measurements; most commonly the 10-metre walk test 270 
(Table IV). However, one did not collect any BFS domain measurements (14, 51) and 271 
another lacked participation domain measurements (15). The intervention period studied 272 
ranged from six weeks (15) – 12 months (51). 273 
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To allow direct comparison of the assumed mechanisms-of-action and functional translation 274 
the following results are presented according to ICF domains. The narrative comparison 275 
found in Table IV is summarised below. Final-assessment meta-analyses are presented first. 276 
There were three overlapping data time-points found at 4-6 weeks, 12-13 weeks and 26-30 277 
weeks for activity domain measurements. These are categorised as short, medium and longer-278 
term respectively (Table IV); meta-analyses at these time-points are then presented. 279 
 280 
BFS 281 
 282 
Physiological cost index (PCI) (15), cadence (45), spatiotemporal/kinematics (44) and lower 283 
limb Fugl-Meyer (16) were reported by single trials; therefore pooled-analysis was not 284 
possible. All the trials found within-group improvements but no significant statistical 285 
differences were reported for any of these measures by the primary authors except Kottink et 286 
al (44) who found some spatiotemporal and kinematic differences in favour of FES (p<0.05) 287 
(Table IV).  288 
 289 
Activity 290 
 291 
Final-assessment outcomes of 10-metre walking speed (all five trials, n=789) and functional 292 
exercise capacity (three trials, n=761) were pooled. Meta-analysis showed between-group 293 
comparable improvement (MD= 0.01, [-0.04, 0.05]; I2=0%; p=0.79, Fig. 2a); and SMD -0.07 294 
[0.22, 0.07], I2=0%; p=0.31, Fig. 3a) respectively. 295 
 296 
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Fig. 2. Activity domain measurement: 10-metre (m) walk test metres per second (m/s)  297 
 298 
Fig. 3. Activity domain measurement: functional exercise capacity metres (m).  299 
 300 
The timed up-and-go test was used in two trials (16, 51), both reported between-group 301 
comparable improvement (p=0.812 and p=0.539), therefore meta-analysis was not required 302 
(Table IV).  303 
All other final-assessment activity measures were used in single trials with between-group 304 
comparable improvement in all cases (Table IV).  305 
Meta-analysis was possible for the 10-metre walk test using data at short (four trials, n=771), 306 
medium (three trials, n=699) and longer-term (three trials, n=713) time-points (Fig. 2b-d). It 307 
revealed comparable improvement in the short-term (MD= 0.02 [-0.05, 0.10]; I2=66%; 308 
p=0.54, Fig. 2b)) and longer-term (MD= -0.00 [-0.04, 0.04]; I2=14%; p=0.95, Fig. 2d)). In 309 
the medium-term there was a marginal, but significant, difference in favour of AFO (MD= -310 
0.04 [-0.09,-0.00]; I2=0%; p=0.04, Fig. 2c)). 311 
Functional exercise capacity meta-analyses were performed for short (three trials, n=761) and 312 
medium-term (two trials, n=692) time-points (Fig. 3b and c). Meta-analyses revealed 313 
between-group comparable improvement (SMD= -0.12 [-0.26-0.02]; I2=0%; p=0.10, Figure 314 
3b) and SMD= -0.10 [-0.25, 0.05]; I2=0%; p=0.19, Fig. 3c)). 315 
 316 
Participation 317 
 318 
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The mobility domain of the Stroke Impact Scale (SIS) was collected by three trials (n=701) 319 
(14, 16, 45). Meta-analysis showed between-group comparable improvement (MD 0.31 [-320 
2.06, 2.68]; I2=41%; p=0.80, Fig. 4). 321 
 322 
Fig. 4. Participation domain measurement: Stroke Impact Scale (mobility sub-scale). 323 
 324 
Activity monitoring was used by two trials (16, 44) (Table IV) but their data collection 325 
methods varied too significantly (steps taken compared to time spent in different positions) to 326 
pool results. Kluding et al (16) found no significant differences in the number of steps taken 327 
and Kottink et al (44) found the FES group spent significantly more time in sitting/lying than 328 
the AFO group (p=0.04).  329 
All other final-assessment participation measurements were used by a single trial (14) with 330 
between-group comparable improvements found (Table IV).  331 
 332 
 333 
DISCUSSION 334 
 335 
This is the first systematic review, including meta-analysis, of studies comparing AFO to 336 
FES as interventions for people with CNO foot-drop which focusses on the clinically relevant 337 
combined-orthotic effects on walking. As a RCT-based review with meta-analysis guided by 338 
the PRISMA statement (55) the results provide the highest level of evidence currently 339 
available to support clinical decision making (42).  340 
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The RCTs were deemed to be of medium-methodological quality, which provides some 341 
confidence in our results that both interventions demonstrate equal combined-orthotic 342 
improvements in 10-metre walking speed, functional exercise capacity, timed-up-and-go and 343 
the mobility sub-scale of the SIS; regardless of the length of time used.  344 
Given the different hypothesized mechanisms-of-action detailed in the introduction it is 345 
somewhat surprising that there was no differentiation between the two interventions for any 346 
of the pooled measurements.  To explore this result we examined outcome measurements 347 
within the BFS domain (which directly reflect mechanisms-of-action (48)) and whether or not 348 
these changes in BFS coincide with changes in activity and participation differentially 349 
between the interventions and over different time-points of use. 350 
 351 
BFS 352 
 353 
 The majority of measurements used in the reviewed trials suggest that there are no 354 
differences between the two interventions. However, given the suggestions of a negative 355 
influence of AFO and a positive influence of FES on volitional muscle activation it was 356 
surprising that none of the included trials reported electromyography (EMG) or strength data. 357 
Throughout our systematic search of the literature we found only one RCT (which explored 358 
therapeutic as opposed to combined-orthotic effects) which compared EMG activity between 359 
FES and AFO treatments. This trial reported that EMG activity was greater following a 360 
period of FES than AFO use (56).  361 
Kottink et al (53) was the only reviewed trial to measure gait features and found differences 362 
between a FES group and an AFO group. Despite these findings, that are supported by results 363 
of non-RCT studies (57-61), no further inferences can be drawn at this time. Future trials 364 
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should capture such measurements to determine whether restorative as opposed to 365 
compensatory changes are made (62) in order to more accurately understand the mechanisms-366 
of-action. 367 
 368 
Activity & Participation 369 
 370 
Meta-analysis of three validated measures of the activity domain (49, 52) and one mobility 371 
specific participation domain measurement (49, 52) indicate that AFOs and FES produce 372 
equivalent functional improvements to walking for people with foot-drop as a result of 373 
stroke; regardless of length of use.  The equivalency of effects between these interventions is 374 
supported by non-RCT studies which have found no significant changes in activity domain 375 
measurements when FES is provided to AFO users (59, 60, 63).  376 
Given the difference in hypothesized mechanisms-of-action between FES and AFO and the 377 
lack of BFS measurements, the question remains as to how these comparable effects on 378 
activity/participation are achieved. One explanation is that both simply correct the 379 
mechanical problem of foot-drop; as is suggested for AFO. However, this does not fully 380 
explain the differences between immediate-orthotic effect and orthotic effect after a period of 381 
use. The activity monitoring results from one trial highlight another potential explanation. 382 
Kluding et al (16) found that the number of steps taken per day increased with use of either 383 
intervention (1891-2069, AFO and 2092-2369, FES at six and 30 weeks). This increase in 384 
repetition of walking in both FES and AFO intervention groups (facilitated by the correction 385 
of foot-drop) could explain the observed comparable improvements. Indeed intensity of task-386 
specific repetition is widely accepted as critical for effective improvements of motor-387 
impairments (64-66). This hypothesis is consistent with Kluding et al’s suggestion that both 388 
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interventions achieve combined-orthotic effects through immediate-orthotic and training 389 
effects (16).  390 
A final hypothesis is that RCTs to date have not been long enough to detect differences given 391 
the predominantly chronic populations investigated (67). Bethoux et al (51) did not find 392 
differences at 12 months which may suggest even longer-term follow up is required (68).  To 393 
facilitate comparisons all future trials should ensure that data collection time-points are 394 
justified against physiological processes underlying treatment effects. 395 
This review had some limitations. Firstly, it has revealed that until 2007 research has been 396 
limited to examinations of a single intervention for a single diagnosis precluding comparisons 397 
between interventions which might usefully inform clinicians which intervention may be 398 
most suitable. Since 2007 comparative RCTs have been undertaken, making this review 399 
timely. Whilst future FES (9, 69) and AFO specific studies (13, 70, 71) are necessary for 400 
intervention development, where possible, research should be impairment focused in order to 401 
facilitate more discerning prescription.  402 
Secondly, despite the literature search encompassing all CNO diagnoses, the reviewed trials 403 
only included participants who had experienced a stroke and who were over the age of 18 so 404 
our results can only be applied to this population. Trials using different CNO populations are 405 
necessary given that current clinical guidelines encompass them. Similarly, in order to form 406 
clinical guidelines indicating which subgroups of patients with any given CNO diagnosis 407 
(e.g. time points post-stroke, severity of foot-drop impairment) might benefit most from 408 
either intervention future studies with carefully defined inclusion/exclusion criteria are 409 
needed.  This approach is of critical importance in subsequent trials so that potentially 410 
important clinical effects are not diluted in heterogeneous study groups. Until such a time as 411 
sufficient high-quality RCTs in specific groups of patients become available any meta-412 
analyses will also suffer similar limitations.  413 
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Thirdly, risk of bias was present in the reviewed studies with detection bias (assessor 414 
blinding) the most common area. While this might impact our results this area of bias is 415 
common within rehabilitation research. Indeed, previous FES (28) and AFO (12) reviews 416 
have chosen to discount it, suggesting it is impractical to address in studies of medical 417 
devices. It can also be argued that objective measures minimize the risk of this source of bias. 418 
However, two trials (15, 16) attempted to control for this, suggesting that it is feasible to 419 
blind assessors and should at least be considered in future trials (72).  We based the quality 420 
assessment on published material alone; so as not to advantage trial authors who respond to 421 
requests for additional data. Therefore a lack of reported methodological detail might account 422 
for some of the other unclear and high areas of bias found. 423 
Finally, the reader should note that a range of different AFO and FES devices were used in 424 
the included trials and our analysis combined these. While combining data from different 425 
types of AFO/FES does not allow a detailed look at the possible different effects of each 426 
individual sub-type, assuming the prescription of devices within each trial was provided on 427 
the basis of clinical judgement and complies with current guidelines, this allows for a 428 
clinically relevant comparison. Furthermore, limited reports of the details of AFO and FES 429 
interventions preclude reliable sub-group analyses. The traditional description of AFOs on 430 
the basis of the material used (carbon fibre, plastic, metal) or mode of manufacture 431 
(customized versus off-the-shelf (54) as with our included trials) should be discontinued. The 432 
mechanical properties (stiffness, mass) of an AFO determine its behaviour (73) so it is these 433 
that should be measured and reported (73-75). Similarly, differences in outcome between 434 
therapist and patient FES setup have been found (76, 77) so this should also be reported. 435 
None of the included trials reported details of FES setup parameters and it remains unclear 436 
which set of parameters would be most useful when comparing across trials; further work is 437 
required in this area.  438 
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In conclusion, despite very different hypothesised mechanisms-of-action for AFO and FES 439 
this RCT, state-of-the-art review, with meta-analysis (39) conservatively indicates that AFOs 440 
have positive combined-orthotic effects on walking that are equivalent to FES for foot-drop 441 
caused by stroke. Methodological and reporting limitations within the current RCT pool 442 
preclude clinical recommendations regarding which type of AFO or FES set-up to use for 443 
particular patient groups from being made; as they do in guiding clinicians which 444 
intervention to prescribe for a specific patient. However crucially, and for the first time, 445 
barriers to achieving such clinical recommendations within research design and reporting 446 
have been identified to progress future research. Furthermore long-term, high-quality RCTs 447 
are required across CNO diagnoses. These should focus on measuring the mechanisms-of-448 
action, whether there is translation of improved impairment to function and reporting the 449 
correct device details; only then will discerning prescription be possible. 450 
 451 
 452 
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Table I. Inclusion Criteria. 701 
702 
Design 
 Randomised Controlled Trials (RCT) 
Participants 
 Participants with foot-drop of a central neurological origin 
Intervention 
 Common peroneal nerve FES to address the specific impairment of foot-drop, 
with or without other areas of stimulation 
 Stimulation eliciting a muscular contraction 
 Trials where common peroneal stimulation is used during walking (overground 
or treadmill) as part of the intervention  
 Trials studying combined-orthotic effects of foot-drop FES 
 Trials where foot-drop FES and another intervention are used in combination but 
foot-drop FES is measured independently 
Comparator 
 Trials comparing foot-drop FES with AFO (the term therapy was allowed as 
might involve AFO) 
Outcomes 
 Measures of walking 
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Table II. Characteristics of included trials, participant and intervention details. 703 
Abbreviations: FES= functional electrical stimulation; AFO=ankle-foot orthosis; *=post intervention/dropout characteristics; +=ITT completed; ~=based on 2007 not 2012 data; †= Pre intervention/drop out 704 
characteristics;  CVA= Cerebrovascular accident/Stroke; ** post intervention/drop characteristics at later time point than is included in this review (12 weeks); yrs=years; mos=months; Customized= custom made/ 705 
modified AFO; Combination= Different AFOs used by different participants; off the shelf= prefabricated/unmodified AFO; ***= both groups continued with physical therapy alongside intervention; TENS= 706 
transcutaneous electrical nerve stimulation with no motor response; wk=week; NESS L300=Bioness model; ODFS= Odstock foot-drop system; AD=all day.  707 
 708 
 709 
 710 
  Trial design N 
Diagnosis 
(R):(L) 
Men: Women  Age (years)  Time since 
diagnosis  
Current or 
new AFO 
users 
AFO Mechanical 
properties 
reported 
FES  Setup for 
measurement done 
by 
Use 
Bethoux (2014 & 
2015)+  
2 arm parallel 
Multiple sites 
495 (242 FES: 
253 AFO)  
CVA 
Not specified 
 
FES=147:95 
AFO=157:96 
FES=63.87 
(11.33) 
AFO=64.3 
(12.01) 
FES=6.9yrs 
(6.43) 
AFO=6.86yrs 
(6.64) 
New  Customized   
 
No  Surface 
Walkaide 
Not specified Home 
2wk progressive wearing schedule 
then AD 
Everaert (2013)* 3 arm crossover 
Multiple sites 
 
78 (43 FES: 35 
AFO)  
CVA 
Not specified 
FES=32:6** 
AFO=19:12** 
FES=57.1  
(12.9)**  
AFO=55.6 
(11.9)** 
FES=6.4mos 
(3.8)** 
AFO=6.9mos 
(3.2)** 
New  Customized 
 
No  Surface 
Walkaide 
Not specified Home 
AD 
Kluding (2013)+ 2 arm parallel 
Multiple sites 
197 (99 FES: 98 
AFO)  
CVA 
93:104 
FES=51:48 
AFO=67:31 
FES=60.71 
(12.24) 
AFO=61.58 
(10.98) 
FES=4.77yrs 
(5.29) 
AFO=4.34yrs 
(4.1) 
Current  Customized*** 
PLUS TENS for 
2wks 
 
No  Surface 
NESS L300 
Not specified Both 
 Bioness clinical 
protocols followed 
15mins-AD 
 Training: 15mins x2 day 
1wk then 20mins 2xday 
next 2wks 
Kottink (2007)*~ 2 arm parallel 
Single site 
29 (14 FES: 15 
AFO)  
CVA 
13:16 
FES=10:04 
AFO=10:05 
FES=55.2 
(11.36) 
AFO=52.87 
(9.87) 
FES=9.07yrs 
(9.29) 
AFO=5.67yrs 
(4.64) 
Current  Combination*** 
 
No  Implanted 
2-channel 
implant 
Not specified Home 
Gradual increase over 2wks, then 
AD 
 
Salisbury (2013)† 2 arm parallel 
Single site 
16 (9 FES: 7 
AFO)  
CVA 
10:6 
 
FES=03:06 
AFO=03:04 
FES=55.8 
(11.3) 
AFO=52.6 
(17.2) 
FES=51.7 
days (34.6) 
New  Off the shelf *** No  Surface 
ODFS 
Clinician for FES Supervised 
Part of physiotherapy 20mins, 5 x 
wk with supervised/ independent 
walking as appropriate. 
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Table III. Risk of Bias. 711 
Abbreviations: L= Low; U=Unclear; H=High. 712 
 713 
 714 
 715 
 716 
 717 
 718 
 719 
 720 
 721 
 722 
 723 
Table IV. Outcome measurements and intervention effects. 724 
 Random sequence 
generation  
(selection bias) 
Allocation concealment 
(selection bias) 
Blinding of 
outcome assessment  
(detection bias) 
Incomplete outcome 
data (attrition bias) 
Selective reporting 
(reporting bias) 
Other 
bias 
Bethoux 
2014/2015 
U H H L L L 
Everaert 2013 U U U H L L 
Kluding 2013 L L U L U L 
Kottink 2007 H U H U L L 
Salisbury 
2013 
H L H U L L 
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 725 
  Walking outcome measures used & ICF level  Outcome collection 
points  
Combined-orthotic effects  
Bethoux et al 
(2014/2015+) 
Activity: 
 10MWT1 
 6min walk test (distance)   
 Gaitrite Functional Ambulation Profile+ 
 mEFAP (including TUG) 
Participation+: 
 SIS (Mobility, ADL/IADL & social participation domains 
combined)1  
 SIS mobility sub-scale  
 Perry ambulation categories based on 10MWT results 
 
0  
Short:1mos (not published) 
Medium: 3mos (not 
published)  
Long:6mos 
12 mos+ 
 FES=AFO 
Everaert et al (2013) BFS:  
 PCI over 4min test1 
Activity:  
 4min walking test (speed)1 
 10MWT  
 Modified RMI 
0, 3wks  
Short: 6wks 
 Modified RMI: between-
group, post-intervention 
differences not reported  
 FES=AFO: for other 
measures 
Kluding et al (2013) BFS:  
 LL Fugl Meyer 
Activity:  
 10MWT (self and fast)1 
 TUG 
 6min walk test (distance)  
Participation: 
 SIS mobility sub-scale 
 Activity monitoring (Stepwatch ®) 
0 
Short: 6 weeks 
Medium: 12 weeks 
Long: 30wks (only change 
data published) 
 FES=AFO 
Kottink et al (2007) BFS:  
 stride time* 
 stride length*  
 stride width*  
 step length*  
 stance phase %* 
 1st double support phase %*  
 1st single support phase %*  
 kinematics=hip, knee & ankle* 
Activity:  
 10MWT 
 6min walk (speed) 
 Speed* 
Participation: 
 Activity monitoring (ActivPAL®) 
0  
Long: 26wks 
 FES>AFO: Longer 1st 
single support phase %*; 
shorter Stance phase; 1st 
double support phase 
%*; Speed*; 10MWT; 
6min walk (speed) at 26 
wks 
 AFO spent less time less 
in sitting/lying than FES 
 FES=AFO: all other 
measures 
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Salisbury et al (2013) BFS: 
 Cadence (10MWT) 
Activity:  
 Speed (10MWT) 
 FAC 
Participation: 
 SIS mobility sub-scale 
 
0  
Short: 6wks  
Medium: 12wks 
 FES=AFO 
 
Abbreviations: wks=weeks; mos=months; min(s)=minute(s); mEFAP=modified Emory Functional Ambulation Profile; TUG=Timed Up and Go; QoL=Quality of Life; SIS=Stroke Impact Scale; ADL/IADL= 726 
Activities of Daily Living/ Instrumental Activities of Daily Living; 10MWT=10-metre walk test; PCI=Physiological Cost Index; RMI=Rivermead Mobility Index; BBS=Berg Balance Scale; *=from Kottink et al 727 
(2012); FAC=Functional Ambulation categories; 1=identified as primary outcome measure by authors; += not reported in Bethoux 2015 12 month follow up publication; =increase; >=greater than; = =equal to; <=less 728 
than. 729 
 730 
 731 
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Fig. 1. Flowchart of trial selection. 732 
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 749 
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 751 
 752 
 753 
 754 
 755 
 756 
Records identified through database searching  
(n = 1593) 
 
MEDLINE 690  CINAHL176 AMED 162  
PEDro 76  CENTRAL 161 clinicaltrials.gov 36 
Naric 189  Scopus 103 
 
Additional records identified 
through other sources  
(n = 243) 
Records after duplicates/obviously irrelevant removed  
(n =703) 
Records screened by titles and 
abstract  
(n = 703) 
Records excluded  
(n =635) 
Reasons include: non-RCT design, not peroneal 
stimulation, not FES, participants were healthy, 
not exploring walking, non-human, technical or 
surgical exploration 
Full-text articles assessed for 
eligibility  
(n = 68) 
Full-text articles excluded  
(n =62) 
 
Many had multiple reasons:- 
Not combined-orthotic effects: 43 
Not RCT: 17 
Not foot-drop: 13 
Not peroneal nerve: 10 
Not functional during walking: 9 
Walking not measured: 6 
Sensory stimulation: 5 
Only FES setups or healthy comparisons: 2 
Potentially relevant: 1 
 
 
 
 
 
Studies included in narrative & 
quantitative synthesis 
(Meta-analysis)  
(n = 7, 2x2 combined so n=5) 
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Fig. 2. Activity measure: 10-metre (m) walk test metres per second (m/s). 757 
 758 
 759 
2a) Final-assessment 760 
 761 
2b) Short-term. Bethoux et al (2014) and Kluding et al (2013) data obtained via 762 
correspondence with authors 763 
 764 
2c) Medium-term. Bethoux et al (2014) and Kluding et al (2013) data obtained via 765 
correspondence with authors 766 
 767 
2d) Longer-term. Kluding et al (2013) data from correspondence with authors 768 
 769 
 770 
 771 
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Fig. 3. Activity measure: Functional exercise capacity metres (m). 772 
 773 
3a) Final-assessment. Kluding et al (2013) data obtained via correspondence with authors. 774 
 775 
3b) Short-term. Bethoux et al (2014) and Kluding et al (2013) data obtained via 776 
correspondence with authors 777 
 778 
3c) Medium-term. Data obtained via correspondence with authors 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
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Fig. 4. Participation measure: Stroke Impact Scale (mobility sub-scale). 788 
789 
  790 
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APPENDIX I 791 
Unpublished data  792 
 Salisbury et al (45) published results were a combination of assisted and unassisted 793 
walking data. On request assisted data was provided.  794 
 Kluding et al (16) published change as opposed to post-intervention data, this was 795 
provided on request.  796 
 Kottink et al (44) only displayed results from their 2007 study in graphical form and 797 
did not respond to request for raw data.  798 
 Bethoux et al (14) published standard error, these were converted to SD (42).  799 
 Both Bethoux et al (14) and Kluding et al (16) provided unpublished time-point data 800 
on request.  801 
 Functional exercise capacity was converted from the speed (metres per second) for 802 
Everaert et al (15). 803 
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